Study: Rifampicin is Likely to be the Safest Latent Tuberculosis Infection Treatment Option
12 Jan, 2020 | 21:26h | UTCAdverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials – The Lancet Infectious Diseases (free registration required)
Commentaries: What is the best regimen to treat latent tuberculosis infection? – The Lancet Infectious Diseases (free) AND Four Months of Rifampicin May Be Best Option for Latent TB – Medscape / Reuters (free registration required)
Related Commentary on Twitter
New study @McGill_TB: “In patients without a contraindication, rifampicin is likely to be the safest latent tuberculosis infection treatment option.” https://t.co/rg2wmcLcqo
— Madhu Pai (@paimadhu) January 9, 2020